VISION & MISSION
With the vision “New Tools Lead to a New World,” EditForce is committed to developing pentatricopeptide repeat (PPR) proteins as the novel, globally standardized, and versatile DNA/RNA editing tools to be used in a variety of species, to bring innovation to pharmaceutical, agricultural, and
We strive for innovation to transform impossible into possible, difficulty into possibility, and inspiration into reality.
|Established||May 15, 2015|
|Capital||90 million yen|
|President and CEO||Takashi Ono|
|Head office||4F Fukuoka Tenjin Fukoku Seimei Bldg. 1-9-17, Tenjin, Chuo-ku, Fukuoka. 810-0001 JAPAN|
|Fukuoka Laboratory||West Zone 5 #430, Kyushu University, 744 Motooka, Nishi-ku, Fukuoka, 819-0395 JAPAN
|Tokyo Office||Shiodome Bldg., 3rd Fl.1-2-20 Kaigan, Minato-ku, Tokyo, 105-0022 JAPAN
|Business area||Application of DNA/ RNA manipulation technology to reagents, pharmaceuticals, agriculture, chemical production etc.|
|Investors||KISCO Ltd., The University of Tokyo Edge Capital Co., Ltd., QB Capital, LLC, Japan Science and Technology Agency, ITOCHU Technology Ventures, Inc., Newton Biocapital SA, K4 Ventures GK (The Kansai Electric Power Group)|
（As of November 1）
West Zone 5 #430, Kyushu University, 744 Motooka, Nishi-ku, Fukuoka, 819-0395 JAPAN
Shiodome Bldg., 3rd Fl.1-2-20 Kaigan, Minato-ku, Tokyo, 105-0022 JAPAN
EditForce was established in 2015. Since then, we have put our effort on the development of PPR proteins as the novel DNA/RNA editing tools, which are to be applied in a variety of fields such as pharmaceuticals, agriculture, and biomanufacturing.
DNA/RNA editing is an expanding field of technology as it is one of the key measures in solving the global issues including health, food, and environment.
Our PPR technology, distinguished from other conventional tools, enables editing of RNA in addition to DNA. As we have reached the stage of putting it into practice, we are eager to collaborate with specialists in each academic/industrial field in need for such novel technology.
To start with, we focus on the field of pharmaceuticals to discover new agents with new mechanisms of action.
Big data of genome DNAs and expressed RNAs of various biological entities along with the AI computing have given significant impact in bioinformatics.
Furthermore, the emergence of genome editing technology potentiating the rational and precise modification of DNA has accelerated the evolution of bioindustry.
EditForce’s novel technology, based on PPR proteins discovered in plants, provides the unprecedented means for RNA editing, in addition to DNA editing that is already in demand.
Discoveries of the vast non-coding RNAs and the complex mechanisms of RNA splicing in humans have given insight into the human biology and their application to the medical field is expected.
Putting the focus on the application of our innovative technology of RNA editing to the medical and pharmaceutical fields in addition to the DNA editing, our challenge continues on.
Our bodies are based on the communications between massive cell populations, and individual cells are controlled by a program called a genome and genome-derived software called RNA. Although genomic information has been decoded via the efforts of many researchers, we still have no means to manipulate cells. We believe that if it becomes possible to manipulate cellular programs freely, the relevant technology would significantly change medical treatments and agriculture. Genome editing technologies were considered a breakthrough in this field, followed only after a few years by a great change in the methods of biological research. We possess novel RNA manipulation technology, and we are convinced that this technology will enable the manipulation of not only the genome but also RNAs, which are more complex, and lead to the creation of a new industry and future.
- Atsushi Usami
- The University of Tokyo Edge Capital Co., Ltd, Partner
- Teruyuki Fukuda
- KISCO LTD. Executive Officer
- Koji Abe
- ITOCHU Technology Ventures, Inc., Vice President
- Toshiyuki Mori
- Newton Biocapital SA, Investment partner
- Yasushi Kojima
- Full-time auditor
- Tomotaka Goji
- The University of Tokyo Edge Capital Co., Ltd, Managing Partner and President
- Yasunobu Akimitsu
- KISCO LTD. Finance and Accounting Depart, General Manager
- Takashi Yamamoto
- Prof., Faculty of Science, Hiroshima Univ.
- ●Imai T, Yagi Y, Nakamura T. Recent Progress Toward RNA Manipulation with Engineered Pentatricopeptide Repeat Proteins in Applied RNA Bioscience (editors: Masuda S, Izawa S) pp. 151-160 (Springer, Singapore, 2018).
- ●Kobayashi T, Yagi Y, Nakamura T. Development of genome dngineering tools from plant-specific PPR proteins using animal cultured cells. Methods Mol Biol 1469, 147-155 (2016).
- ●Yagi Y, Shirakawa M, Nakamura T. The challenges faced by EditForce Inc., to go beyond genome editing. Nature 528 suppl (2015).
- ●Okuda K, Shoki H, Arai M, Shikanai T, Small I, Nakamura T. Quantitative analysis of motifs contributing to the interaction between PLS-subfamily members and their target RNA sequences in plastid RNA editing. Plant J 80, 870-882 (2014).
- ●Yagi Y, Nakamura T, Small I. The potential for manipulating RNA with pentatricopeptide repeat proteins. Plant J 78, 772-782 (2014).
- ●Yagi Y, Tachikawa M, Noguchi H, Satoh S, Obokata J, Nakamura T. Pentatricopeptide repeat proteins involved in plant organellar RNA editing. RNA Biol 10, 1419-1425 (2013).
- ●Yagi Y, Hayashi S, Kobayashi K, Hirayama T, Nakamura T. Elucidation of the RNA recognition code for pentatricopeptide repeat proteins involved in organelle RNA editing in plants. PLoS ONE 8, e57286 (2013).
- ●Nakamura T, Yagi Y, Kobayashi K. Mechanistic insight into pentatricopeptide repeat proteins as sequence-specific RNA-binding proteins for organellar RNAs in plants. Plant Cell Physiol 53, 1171-1179 (2012).
- ●Kobayashi K, Kawabata M, Hisano K, Kazama T, Matsuoka K, Sugita M, Nakamura T. Identification and characterization of the RNA binding surface of the pentatricopeptide repeat protein. Nucleic Acids Res 40, 2712-2723 (2012).